BioPharmSignal logoBioPharmSignal

Biotech News

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MacroGenics (MGNX)MacroGenicsEarnings

Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)

Related news

REGNRegeneron Pharmaceuticals2026-07-30 10:30 EST

Regeneron Reports Second Quarter 2026 Financial and Operating Results

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

IMCRImmunocore Holdings plc2026-08-06 11:00 EST

Immunocore reports second quarter financial results and provides a business update

View all latest news

MacroGenics

Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates. ADC Portfolio MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid...

Recent company news

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

MGNXMacroGenics2026-07-02 13:25 EST

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

MGNXMacroGenics2026-06-22 20:43 EST

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

Stock data

Close
4.06 USD
Market cap
257.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States